Literature DB >> 16970801

Heparanase induces tissue factor expression in vascular endothelial and cancer cells.

Y Nadir1, B Brenner, A Zetser, N Ilan, I Shafat, E Zcharia, O Goldshmidt, I Vlodavsky.   

Abstract

BACKGROUND: Over-expression of tissue factor (TF) and activation of the coagulation system are common in cancer patients. Heparanase is an endo-beta-D-glucuronidase that cleaves heparan sulfate chains on cell surfaces and in the extracellular matrix, activity that closely correlates with cell invasion, angiogenesis and tumor metastasis. The study was undertaken to investigate the involvement of heparanase in TF expression.
METHODS: Tumor-derived cell lines were transfected with heparanase cDNA and TF expression was examined. The effect of exogenous addition of active and inactive heparanase on TF expression and activity was studied in tumor cell lines and primary human umbilical vein endothelial cells. TF expression was also explored in heparanase over-expressing transgenic (Tg) mice. Blast cells were collected from acute leukemia patients and TF and heparanase expression levels were analyzed.
RESULTS: Over-expression of heparanase in tumor-derived cell lines resulted in a 2-fold increase in TF expression levels, and a similar trend was observed in heparanase Tg mice in vivo. Likewise, exogenous addition of heparanase to endothelial or tumor-derived cells resulted in enhanced TF expression and activity. Interestingly, TF expression was also induced in response to enzymatically inactive heparanase, suggesting that this effect was independent of heparanase enzymatic activity. The regulatory effect of heparanase on TF expression involved activation of the p38 signaling pathway. A positive correlation between TF expression levels and heparanase activity was found in blasts collected from 22 acute leukemia patients.
CONCLUSIONS: Our results indicate that in addition to its well-known function as an enzyme paving a way for invading cells, heparanase also participates in the regulation of TF gene expression and its related coagulation pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16970801     DOI: 10.1111/j.1538-7836.2006.02212.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  41 in total

1.  Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.

Authors:  Miry Blich; Amnon Golan; Gil Arvatz; Anat Sebbag; Itay Shafat; Edmond Sabo; Victoria Cohen-Kaplan; Sirouch Petcherski; Shani Avniel-Polak; Amnon Eitan; Haim Hammerman; Doron Aronson; Elena Axelman; Neta Ilan; Gabriel Nussbaum; Israel Vlodavsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

2.  High glucose facilitated endothelial heparanase transfer to the cardiomyocyte modifies its cell death signature.

Authors:  Fulong Wang; Jocelyn Jia; Nathaniel Lal; Dahai Zhang; Amy Pei-Ling Chiu; Andrea Wan; Israel Vlodavsky; Bahira Hussein; Brian Rodrigues
Journal:  Cardiovasc Res       Date:  2016-12       Impact factor: 10.787

Review 3.  Perioperative events influence cancer recurrence risk after surgery.

Authors:  Jonathan G Hiller; Nicholas J Perry; George Poulogiannis; Bernhard Riedel; Erica K Sloan
Journal:  Nat Rev Clin Oncol       Date:  2017-12-28       Impact factor: 66.675

Review 4.  Tumorigenic and adhesive properties of heparanase.

Authors:  Flonia Levy-Adam; Neta Ilan; Israel Vlodavsky
Journal:  Semin Cancer Biol       Date:  2010-07-07       Impact factor: 15.707

5.  Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression.

Authors:  Victoria Cohen-Kaplan; Ilana Doweck; Inna Naroditsky; Israel Vlodavsky; Neta Ilan
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Gil Arvatz; Svetlana Gingis-Velitski; Flonia Levy-Adam; Ofer Nativ; Ronen Shemesh; Michal Ayalon-Sofer; Neta Ilan; Israel Vlodavsky
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

Review 7.  Mechanisms of heparanase inhibitors in cancer therapy.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Exp Hematol       Date:  2016-08-26       Impact factor: 3.084

Review 8.  Involvement of heparanase in atherosclerosis and other vessel wall pathologies.

Authors:  Israel Vlodavsky; Miry Blich; Jin-Ping Li; Ralph D Sanderson; Neta Ilan
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

9.  Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment.

Authors:  Itay Shafat; Ayelet Ben Barak; Sergey Postovsky; Ronit Elhasid; Neta Ilan; Israel Vlodavsky; Miriam Weyl Ben Arush
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

10.  Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.

Authors:  Victoria Cohen-Kaplan; Inna Naroditsky; Anna Zetser; Neta Ilan; Israel Vlodavsky; Ilana Doweck
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.